MedTrace Logo

MSC Infusion for Anti-aging and Regenerative Therapy

NCT04174898 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-11-22

No results posted yet for this study

Summary

To evaluate the safety and efficacy of human Mesenchymal Stem Cell (hMSC) infusion therapy, in preserving general wellness and ameliorating or reversing the effects of aging in our study population

Conditions

  • Aging Well
  • Regenerative Medicine

Interventions

BIOLOGICAL

human Mesenchymal Stem Cell (MSC) infusion therapy

Subjects will be infused with 100million human MSCs

Sponsors & Collaborators

  • CytoMed Therapeutics Pte Ltd

    collaborator INDUSTRY

  • Landmark Medical Centre Sdn Bhd

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2021-04-14
Completion
2022-04-14

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04174898 on ClinicalTrials.gov